Acrivon Therapeutics, Inc. ("Acrivon” or "Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage precision medicine company ...

BioNTech and Biotheus presented data on the drug at the European cancer meeting ESMO in September, hinting at its potential .

Good morning and welcome to Agenus' third quarter 2024 conference call and webcast. All participants will be in a listen-only ...

We look forward to initiating an adaptive platform trial, starting with sub-study 1 randomizing patients with relapsed PSOC to single agent COM701 maintenance treatment or placebo in the second ...

Completed Pre-Biologics License Application (BLA) meeting with the U.S. Food and Drug Administration (FDA) and remain on track to submit a BLA ...

EMA granted clearance to advancebelrestotug 400mg + dostarlimab as recommended Phase 3 dose and activate GALAXIES Lung-301 clinical sites in ...

Agenus Inc. ("Agenus" or the "Company") (Nasdaq: AGEN), an immuno-oncology company focused on innovation, today provided a corporate update and reported financial ...

Net financial result for the three and nine months ended September 30, 2024, amounted to €2.2 million and €8.0 million, or a decrease of €3.1 million and €4.7 million, from €5.3 million and €12.7 ...

The outcome of the primary endpoint of PFS is projected to be available in the first half of 2025, potentially followed by a BLA submission ... at the 2024 European Society of Medical Oncology (ESMO) ...

New results from a pooled analysis of patients will be featured in a late-breaking presentation at the upcoming European ...

Wet and wild ocean exploration sequel Subnautica 2 was announced at the Xbox Partner preview will arrive on PC and Xbox Series X and S in 2025 via the Xbox Game Preview program. It'll also be ...

November 6, 2024Personalis, Inc. misses on earnings expectations. Reported EPS is $-0.64 EPS, expectations were $-0.33.